Gilead Sciences #61958-2002-02 Descovy® Emtricitabine / Tenofovir Alafenamide 200 mg - 25 mg Tablet Bottle 30 Blister Tablets 30/BO INDICATION & LIMITATION OF USE DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation. Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated. 30 visually trackable doses, with a helpful refill reminder built in Convenient packaging with perforated doses
Size: 200MG
More Information
